Skip to main content

Table 2 Relative mRNA expression in endothelial cells, with and without TGF-β1

From: Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis

 

Day 7

Day 21

TGF-β1

+

+

CTGF

3.49 ± 0.54

4.84 ± 0.10

1.27 ± 0.41

2.61 ± 0.14

PDGF-C

16.0 ± 0.07

22.8 ± 0.29

24.4 ± 0.37

79.5 ± 0.56*

eNOS

1.75 ± 0.21

0.16 ± 0.42**

1.59 ± 0.11

0.07 ± 0.71**

iNOS

3.20 ± 0.02

0.24 ± 0.32**

4.05 ± 0.28

0.11 ± 0.75**

Twist-1

2.76 ± 0.31

7.95 ± 0.23**

3.71 ± 0.72

14.3 ± 0.59*

α-SMA

5.60 ± 0.80

18.6 ± 0.16*

4.97 ± 0.29

35.8 ± 0.29*

  1. The table shows gene expression of connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF)-C, inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS), Twist-1, and α-smooth muscle actin (α-SMA) in lung endothelial cells from bleomycin-treated mice, with and without TGF-β1 (10 mg/mL) treatment. mRNA levels were determined by quantitative real time-PCR. Total RNA was isolated from endothelial cells at 7 and 21 days after bleomycin administration. PCR was performed using three to four independently prepared cDNA samples from endothelial cells. Results were normalized to expression levels in endothelial cells from untreated lungs at day 0 and are expressed as fold-changes. Data are means ± standard error of the mean, from three or four mice
  2. *p < 0.05 versus cells without TGF-β1
  3. **p < 0.01 versus cells without TGF-β1 on day 21 and with TGF-β1 on day 7